drugset / Trial / NCT05971251
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Phase 1
Active not recruiting
24 enrolled
University of Alabama at Birmingham
ADC Therapeutics S.A. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.
Timeline
- Start
- 2023-12-18
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | — |
| Subject | Loncastuximab Tesirine | Other / unclassified | 45 ug/kg | Intravenous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 60 ug/kg | Intravenous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 75 ug/kg | Intravenous |